Literature DB >> 6352137

Influence of food intake on presystemic clearance of drugs.

A Melander, A McLean.   

Abstract

Many drugs have a low degree of oral bioavailability even though their gastrointestinal absorption is complete. This is because they undergo extensive presystemic metabolic transformation during the first passage of the drug through the gastrointestinal mucosa and the liver. In addition to effects on the absorption of some drugs, food intake has been found to influence the bioavailability of drugs with extensive presystemic metabolic clearance. Extensive presystemic clearance occurs commonly with compounds that are lipophilic bases, e.g. propranolol and amitriptyline, but rarely if ever with lipophilic acids, e.g. salicylic acid and penicillin, except for esters of such acids, e.g. acetylsalicylic acid (aspirin) and pivampicillin. While presystemic clearance of (esterified) acidic drugs is unaffected by food, concurrent food intake markedly reduces presystemic clearance, and thus enhances bioavailability, of several lipophilic bases. Among these are propranolol, metoprolol, labetalol, dixyrazine and hydralazine, which are presystemically metabolised by hydroxylation, glucuronidation and acetylation enzymes systems. In contrast, the bioavailability of lipophilic bases which undergo presystemic dealkylation (amitriptyline, codeine, dextropropoxyphene, prazosin, zimelidine) is unaffected by concurrent food intake. Food intake reduces presystemic clearance of hydralazine and propranolol when these drugs are administered in conventional rapid-release tablets but not when they are given in slow-release formulations. Likewise, coadministration of hydralazine reduces presystemic clearance of rapid-release but not slow-release propranolol. These and other observations favour the view that food may reduce presystemic clearance of (certain) lipophilic basic drugs via transient, complex effects on splanchnic-hepatic blood flow and/or shunt processes, and that the extent of this effect is influenced by the rate of drug delivery to the liver. In addition, these findings refute the notion that the reduced presystemic clearance results from (long-lasting) hepatic enzyme inhibition by some nutrient. On the other hand, repeated intake of specific nutrients (protein) and food contaminants (benzpyrene) can enhance presystemic drug clearance by enzyme induction. Thus, food may exert a dual effect on presystemic drug clearance. A complete evaluation of the influence of food on presystemic drug clearance necessitates bioavailability studies carried out following both single and repeated meals, including different kinds of food prepared by various cooking methods. The influence of food on the presystemic clearance of drugs is most likely to be clinically relevant with drugs having narrow therapeutic margins and/or steep dose-response curves.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6352137     DOI: 10.2165/00003088-198308040-00002

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN: 0312-5963            Impact factor:   6.447


  46 in total

1.  Enhancement of the bioavailability of propranolol and metoprolol by food.

Authors:  A Melander; K Danielson; B Scherstén; E Wåhlin
Journal:  Clin Pharmacol Ther       Date:  1977-07       Impact factor: 6.875

2.  Influence of the route of administration on the area under the plasma concentration-time curve.

Authors:  P A Harris; S Riegelman
Journal:  J Pharm Sci       Date:  1969-01       Impact factor: 3.534

3.  Comparative In Vitro Effects and In Vivo Kinetics of Antithyroid Drugs.

Authors:  A Melander; B Hallengren; S Rosendal-Helgesen; A K Sjöberg; E Wählin-Boll
Journal:  Eur J Clin Pharmacol       Date:  1980-04       Impact factor: 2.953

4.  Enhancement of dicoumarol bioavailability by concomitant food intake.

Authors:  A Melander; E Wåhlin
Journal:  Eur J Clin Pharmacol       Date:  1978-12-18       Impact factor: 2.953

Review 5.  The function of the hepatic artery.

Authors:  A M Rappaport; J H Schneiderman
Journal:  Rev Physiol Biochem Pharmacol       Date:  1976       Impact factor: 5.545

6.  The effect of food and clopamide on the absorption of pindolol in man.

Authors:  J L Kiger; D Lavene; M F Guillaume; M Guerret; J Longchampt
Journal:  Int J Clin Pharmacol Biopharm       Date:  1976-04

7.  Influence of food on the absorption of phenytoin in man.

Authors:  A Melander; G Brante; O Johansson; T Lindberg; E Wåhlin-Boll
Journal:  Eur J Clin Pharmacol       Date:  1979-05-21       Impact factor: 2.953

8.  Gastrointestinal absorption of hydrochlorothiazide enhanced by concomitant intake of food.

Authors:  B Beermann; M Groschinsky-Grind
Journal:  Eur J Clin Pharmacol       Date:  1978-05-17       Impact factor: 2.953

9.  Interaction between oral propranolol and hydralazine.

Authors:  A J McLean; H Skews; A Bobik; F J Dudley
Journal:  Clin Pharmacol Ther       Date:  1980-06       Impact factor: 6.875

10.  Stable oral availability of sustained release propranolol when co-administered with hydralazine or food: evidence implicating substrate delivery rate as a determinant of presystemic drug interactions.

Authors:  A J Byrne; J J McNeil; P M Harrison; W Louis; A M Tonkin; A J McLean
Journal:  Br J Clin Pharmacol       Date:  1984       Impact factor: 4.335

View more
  38 in total

Review 1.  The mucosa of the small intestine: how clinically relevant as an organ of drug metabolism?

Authors:  Margaret M Doherty; William N Charman
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

Review 2.  Pharmacokinetics of drugs in overdose.

Authors:  Y J Sue; M Shannon
Journal:  Clin Pharmacokinet       Date:  1992-08       Impact factor: 6.447

3.  Possible interactions between dietary fibres and 5-aminosalicylic acid [corrected].

Authors:  Camilla Henriksen; Steen Hansen; Inge Nordgaard-Lassen; Jens Rikardt Anderson; Pia Madsen
Journal:  Therap Adv Gastroenterol       Date:  2010-01       Impact factor: 4.409

Review 4.  Effects of food on the clinical pharmacokinetics of anticancer agents: underlying mechanisms and implications for oral chemotherapy.

Authors:  Brahma N Singh; Bimal K Malhotra
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

Review 5.  Clinical significance of pharmacokinetic models of hepatic elimination.

Authors:  D J Morgan; R A Smallwood
Journal:  Clin Pharmacokinet       Date:  1990-01       Impact factor: 6.447

6.  The influence of food on the pharmacokinetics of 'biphasic' nifedipine at steady state in normal subjects.

Authors:  G H Rimoy; J R Idle; N K Bhaskar; P C Rubin
Journal:  Br J Clin Pharmacol       Date:  1989-11       Impact factor: 4.335

Review 7.  The effects of food on drug bioavailability.

Authors:  P A Winstanley; M L Orme
Journal:  Br J Clin Pharmacol       Date:  1989-12       Impact factor: 4.335

8.  A predictive model for exemestane pharmacokinetics/pharmacodynamics incorporating the effect of food and formulation.

Authors:  Marta Valle; Enrico Di Salle; Maria Gabriella Jannuzzo; Italo Poggesi; Maurizio Rocchetti; Riccardo Spinelli; Davide Verotta
Journal:  Br J Clin Pharmacol       Date:  2005-03       Impact factor: 4.335

Review 9.  Influence of diet and nutritional status on drug metabolism.

Authors:  I Walter-Sack; U Klotz
Journal:  Clin Pharmacokinet       Date:  1996-07       Impact factor: 6.447

10.  Influences of the calcium antagonists nicardipine and nifedipine, and the calcium agonist BAY-K-8644, on the pharmacokinetics of propranolol in rats.

Authors:  I Vercruysse; D F Schoors; D L Massart; A G Dupont
Journal:  Cardiovasc Drugs Ther       Date:  1993-08       Impact factor: 3.727

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.